Research
Print page Print page
Switch language
Rigshospitalet - a part of Copenhagen University Hospital
Published

Anti-TNF-α biotherapies: perspectives for evidence-based personalized medicine

Research output: Contribution to journalJournal articleResearchpeer-review

DOI

  1. Pattern recognition receptor polymorphisms in early periodontitis

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Lewis and AB0 blood group-phenotypes in periodontitis, cardiovascular disease, obesity and stroke

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Gasotransmitters and the immune system: Mode of action and novel therapeutic targets

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Biological anti-TNF drugs: immunogenicity underlying treatment failure and adverse events

    Research output: Contribution to journalReviewResearchpeer-review

View graph of relations
This article discusses the rationale behind recommending immunopharmacological guidance of long-term therapies with genetically engineered anti-TNF-α immunoglobulin constructs. Arguments why therapeutic decision-making should not rely on clinical outcome alone are presented. Central to this is that the use of theranostics (i.e., monitoring circulating levels of functional anti-TNF-α drugs and antidrug antibodies) would markedly improve treatment because therapies can be tailored to individual patients and provide more effective and economical long-term therapies with minimal risk of side effects. Large-scale immunopharmacological knowledge of how patients 'handle' TNF-α biopharmaceuticals would also help industry develop more effective and safer TNF-α inhibitors.
Original languageEnglish
JournalImmunotherapy
Volume4
Issue number11
Pages (from-to)1167-79
Number of pages13
ISSN1750-743X
DOIs
Publication statusPublished - 2012

ID: 36820138